Masaru Matsuda News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Masaru matsuda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Masaru Matsuda Today - Breaking & Trending Today

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $15,992.75 in Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Masaru Matsuda sold 1,775 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $9.01, for a total transaction of $15,992.75. Following the transaction, the insider now directly owns 188,508 shares in the […] ....

Masaru Matsuda , Arcutis Biotherapeutics , Franklin Resources Inc , Goldman Sachs Group , Farallon Capital Management , Arcutis Biotherapeutics Inc , Jennison Associates , Opaleye Management Inc , Securities Exchange Commission , Arcutis Biotherapeutics Company Profile , Needham Company , Get Free Report , Exchange Commission , Point Capital ,

Needham & Company LLC Increases Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00

Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price objective upped by Needham & Company LLC from $16.00 to $18.00 in a research report released on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock. Other equities analysts have also recently issued research reports about the company. The […] ....

Arcutis Biotherapeutics , Masaru Matsuda , Pricet Rowe Associates Inc , Deutsche Bank , Ameritas Investment Partners Inc , Needham Company , Arcutis Biotherapeutics Inc , Goldman Sachs Group , Proshare Advisors , Securities Exchange Commission , Free Report , Moderate Buy , Get Free Report , Exchange Commission , Share Advisors , Investment Partners ,

Needham & Company LLC Boosts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00

Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price objective lifted by Needham & Company LLC from $16.00 to $18.00 in a research report sent to investors on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock. Several other research firms have also commented on ARQT. Mizuho boosted […] ....

Masaru Matsuda , Arcutis Biotherapeutics , Jump Financial , Goldman Sachs Group , Arcutis Biotherapeutics Inc , Jennison Associates , Needham Company , York Mellon Corp , Swiss National Bank , Free Report , Moderate Buy , Get Free Report , New York Mellon Corp , National Bank ,